Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

A compound according to Formula I:

• wherein
• Cy is phenyl, or 5-6 membered heteroaryl comprising one, two or three N atoms;
• L1 is a single bond, —O—, —C(═O)—, —C(═O)O—, —S(O)2—, —NR6a—, —C(═O)NR6b—, —S(O)2NR6c—, or —C(═O)NR6dS(O)2—;
• R1 is:
• H,
• C1-6 alkyl optionally substituted with one or more independently selected
• OH,
• halo,
• C1-4 alkoxy,
• NR7aR7b,
• —C(═O)OH—,
• —C(═O)NRcRd,
• —C(═O)OC1-4 alkyl, or
• 4-8 membered monocyclic heterocycloalkyl comprising one, two, or three heteroatoms independently selected from N, S, and O;
• C3-7 cycloalkyl optionally substituted with one or more OH, C1-4 alkoxy, or
• 4-9 membered monocyclic or spirobicyclic or bridged or fused bicyclic heterocycloalkyl comprising one, two, or three heteroatoms independently selected from N, S, and O;
• which heterocycloalkyl is optionally substituted with one or more independently selected R11 groups;
• each R11 is independently:
• OH,
• CN,
• halo,
• oxo,
• —NR8aR8b,
• C3-7 cycloalkyl,
• C1-4 alkyl optionally substituted with one or more independently selected halo, OH, C1-4 alkoxy, —NR9aR9b,
• C1-4 alkoxy optionally substituted with one C1-4 alkoxy,
• 4-7 membered monocyclic heterocycloalkyl comprising one, two, or three heteroatoms independently selected from N, S, and O,
• C(═O)OC1-4alkyl, or
• —NR8cC(═O)OC1-4alkyl;
• R2 is
• halo,
• CN, or
• C1-4 alkyl;
• the subscript n is 0, or 1;
• L2 is O, or —NR4—,
• R3 is
• C1-6alkyl optionally substituted with one or more independently selected
• halo, or
• C3-7 cycloalkyl,
• Phenyl substituted with one R5a group and one or two independently selected R5b groups,
• 6-membered heteroaryl comprising one or two N atoms, substituted with one R5a group and one or two independently selected R5b groups,
• 4-10 membered monocyclic or fused, bridged or spiro bicyclic heterocycloalkyl comprising one or two heteroatoms independently selected from N, S, and O, optionally substituted with one, two or three groups independently selected from R5a and R5b, or
• 4-10 membered monocyclic or fused, bridged or spiro bicyclic cycloalkyl, optionally substituted with one, two or three groups independently selected from R5a and R5b;
• R4 is
• H,
• C1-4 alkyl optionally substituted with one or more independently selected OH or C1-4 alkoxy, or
• C3-7 cycloalkyl;
• R5a is —CN, —SO2—C1-4 alkyl, or —CF3;
• each R5b is independently selected from halo, C1-4 alkyl, and C3-7 cycloalkyl;
• each R7a, and R7b is independently selected from
• H, and
• C1-4 alkyl optionally substituted with one —NR10aR10b;
• and
• each R6a, R6b, R6c, R6d, R7c, R7d, R8a, R8b, R8c, R9a, R9b, R10a, and R10b is independently selected from H, and C1-4 alkyl;
• or a pharmaceutically acceptable salt thereof, or a solvate or the solvate of a pharmaceutically acceptable salt thereof.